68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data
The aim of the present study is to investigate and compare the performances of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in identifying recurrent prostate cancer (PCa) after primary treatment and to explore the association of dual-tracer PET findings with clinical and histopathological characteristics. Th...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-01, Vol.14 (2), p.334 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 334 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Mapelli, Paola Ghezzo, Samuele Samanes Gajate, Ana Maria Preza, Erik Palmisano, Anna Cucchiara, Vito Brembilla, Giorgio Bezzi, Carolina Rigamonti, Riccardo Magnani, Patrizia Toninelli, Elisa Bettinardi, Valentino Suardi, Nazareno Gianolli, Luigi Scifo, Paola Briganti, Alberto De Cobelli, Francesco Esposito, Antonio Picchio, Maria |
| description | The aim of the present study is to investigate and compare the performances of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in identifying recurrent prostate cancer (PCa) after primary treatment and to explore the association of dual-tracer PET findings with clinical and histopathological characteristics. Thirty-five patients with biochemical relapse (BCR) of PCa underwent 68Ga PSMA PET/MRI for restaging purpose, with 31/35 also undergoing 68Ga-DOTA-RM2 PET/MRI scan within 16 days (mean: 3 days, range: 2–16 days). Qualitative and quantitative image analysis has been performed by comparing 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI findings both on a patient and lesion basis. Clinical and instrumental follow-up was used to validate PET findings. Fisher’s exact test and Mann-Whitney U test were used to investigate the association between dual-tracer PET findings, clinical and histopathological data. p-value significance was defined below the 0.05 level. Patients’ mean age was 70 years (range: 49–84) and mean PSA at time of PET/MR scans was 1.88 ng/mL (range: 0.21–14.4). A higher detection rate was observed for 68Ga-PSMA PET/MRI, with more lesions being detected compared to 68Ga-DOTA-RM2 PET/MRI (26/35 patients, 95 lesions vs. 15/31 patients, 41 lesions; p = 0.016 and 0.002). 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI findings were discordant in 11/31 patients; among these, 10 were 68Ga-PSMA positive (9/10 confirmed as true positive and 1/10 as false positive by follow-up examination). Patients with higher levels of PSA and shorter PSA doubling time (DT) presented more lesions on 68Ga-PSMA PET/MRI (p = 0.006 and 0.044), while no association was found between PET findings and Gleason score. 68Ga-PSMA has a higher detection rate than 68Ga-DOTA-RM2 in detecting PCa recurrence. The number of 68Ga-PSMA PET positive lesions is associated with higher levels of PSA and shorter PSA DT, thus representing potential prognostic factors. |
| doi_str_mv | 10.3390/cancers14020334 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8773792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2622282356</sourcerecordid><originalsourceid>FETCH-LOGICAL-c328t-8a0aa9d56d611b01c983548ecbb351f76881b0e593ebfbd4903ff3d569d17e23</originalsourceid><addsrcrecordid>eNpdkV9v2yAUxdG0qq26PvcVaS978QJcG8weJkVJ_0mNGqV5tzDGCZUDGeBN-xj9xrPdatrKC3DOT-dyuQhdUfIVQJKZVk6bEGlOGAHIP6BzRgTLOJf5x3_OZ-gyxmcyLAAquDhFZ1CQAnIpz9ELL29Vtn5azbFyDZ5uy8ftPNusGF5fb2erzT22Dm-M7kMwLuF18DGpZPBiKv8NL63auUGzGq9NaH04jMYUN4_Ra6uS9Q7_smmPF511Vqtucu9sTP6o0t53fjepS5XUJ3TSqi6ay7f9Am1vrreLu-zh8fZ-MX_INLAyZaUiSsmm4A2ntCZUyxKKvDS6rqGgreBlOcimkGDqtm5ySaBtYeBlQ4VhcIG-v8Ye-_pgGj20FlRXHYM9qPC78spW_zvO7qud_1mVQoCQY8CXt4Dgf_QmpupgozZdp5zxfawYZ4yVDAo-oJ_foc--D27obqQoE0LCSM1eKT38cAym_fsYSqpx4NW7gcMfm0mdeg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2621277936</pqid></control><display><type>article</type><title>68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Mapelli, Paola ; Ghezzo, Samuele ; Samanes Gajate, Ana Maria ; Preza, Erik ; Palmisano, Anna ; Cucchiara, Vito ; Brembilla, Giorgio ; Bezzi, Carolina ; Rigamonti, Riccardo ; Magnani, Patrizia ; Toninelli, Elisa ; Bettinardi, Valentino ; Suardi, Nazareno ; Gianolli, Luigi ; Scifo, Paola ; Briganti, Alberto ; De Cobelli, Francesco ; Esposito, Antonio ; Picchio, Maria</creator><creatorcontrib>Mapelli, Paola ; Ghezzo, Samuele ; Samanes Gajate, Ana Maria ; Preza, Erik ; Palmisano, Anna ; Cucchiara, Vito ; Brembilla, Giorgio ; Bezzi, Carolina ; Rigamonti, Riccardo ; Magnani, Patrizia ; Toninelli, Elisa ; Bettinardi, Valentino ; Suardi, Nazareno ; Gianolli, Luigi ; Scifo, Paola ; Briganti, Alberto ; De Cobelli, Francesco ; Esposito, Antonio ; Picchio, Maria</creatorcontrib><description>The aim of the present study is to investigate and compare the performances of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in identifying recurrent prostate cancer (PCa) after primary treatment and to explore the association of dual-tracer PET findings with clinical and histopathological characteristics. Thirty-five patients with biochemical relapse (BCR) of PCa underwent 68Ga PSMA PET/MRI for restaging purpose, with 31/35 also undergoing 68Ga-DOTA-RM2 PET/MRI scan within 16 days (mean: 3 days, range: 2–16 days). Qualitative and quantitative image analysis has been performed by comparing 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI findings both on a patient and lesion basis. Clinical and instrumental follow-up was used to validate PET findings. Fisher’s exact test and Mann-Whitney U test were used to investigate the association between dual-tracer PET findings, clinical and histopathological data. p-value significance was defined below the 0.05 level. Patients’ mean age was 70 years (range: 49–84) and mean PSA at time of PET/MR scans was 1.88 ng/mL (range: 0.21–14.4). A higher detection rate was observed for 68Ga-PSMA PET/MRI, with more lesions being detected compared to 68Ga-DOTA-RM2 PET/MRI (26/35 patients, 95 lesions vs. 15/31 patients, 41 lesions; p = 0.016 and 0.002). 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI findings were discordant in 11/31 patients; among these, 10 were 68Ga-PSMA positive (9/10 confirmed as true positive and 1/10 as false positive by follow-up examination). Patients with higher levels of PSA and shorter PSA doubling time (DT) presented more lesions on 68Ga-PSMA PET/MRI (p = 0.006 and 0.044), while no association was found between PET findings and Gleason score. 68Ga-PSMA has a higher detection rate than 68Ga-DOTA-RM2 in detecting PCa recurrence. The number of 68Ga-PSMA PET positive lesions is associated with higher levels of PSA and shorter PSA DT, thus representing potential prognostic factors.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14020334</identifier><identifier>PMID: 35053499</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Antigens ; Cancer therapies ; Gastrin ; Gastrin-releasing peptide ; Image processing ; Lesions ; Localization ; Magnetic resonance imaging ; Metastasis ; Patients ; Pelvis ; Positron emission tomography ; Prostate cancer ; Proteins ; Tomography</subject><ispartof>Cancers, 2022-01, Vol.14 (2), p.334</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c328t-8a0aa9d56d611b01c983548ecbb351f76881b0e593ebfbd4903ff3d569d17e23</citedby><cites>FETCH-LOGICAL-c328t-8a0aa9d56d611b01c983548ecbb351f76881b0e593ebfbd4903ff3d569d17e23</cites><orcidid>0000-0002-7532-6211 ; 0000-0002-7765-6759 ; 0000-0003-3554-4609 ; 0000-0003-4014-3711</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773792/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773792/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Mapelli, Paola</creatorcontrib><creatorcontrib>Ghezzo, Samuele</creatorcontrib><creatorcontrib>Samanes Gajate, Ana Maria</creatorcontrib><creatorcontrib>Preza, Erik</creatorcontrib><creatorcontrib>Palmisano, Anna</creatorcontrib><creatorcontrib>Cucchiara, Vito</creatorcontrib><creatorcontrib>Brembilla, Giorgio</creatorcontrib><creatorcontrib>Bezzi, Carolina</creatorcontrib><creatorcontrib>Rigamonti, Riccardo</creatorcontrib><creatorcontrib>Magnani, Patrizia</creatorcontrib><creatorcontrib>Toninelli, Elisa</creatorcontrib><creatorcontrib>Bettinardi, Valentino</creatorcontrib><creatorcontrib>Suardi, Nazareno</creatorcontrib><creatorcontrib>Gianolli, Luigi</creatorcontrib><creatorcontrib>Scifo, Paola</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><creatorcontrib>De Cobelli, Francesco</creatorcontrib><creatorcontrib>Esposito, Antonio</creatorcontrib><creatorcontrib>Picchio, Maria</creatorcontrib><title>68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data</title><title>Cancers</title><description>The aim of the present study is to investigate and compare the performances of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in identifying recurrent prostate cancer (PCa) after primary treatment and to explore the association of dual-tracer PET findings with clinical and histopathological characteristics. Thirty-five patients with biochemical relapse (BCR) of PCa underwent 68Ga PSMA PET/MRI for restaging purpose, with 31/35 also undergoing 68Ga-DOTA-RM2 PET/MRI scan within 16 days (mean: 3 days, range: 2–16 days). Qualitative and quantitative image analysis has been performed by comparing 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI findings both on a patient and lesion basis. Clinical and instrumental follow-up was used to validate PET findings. Fisher’s exact test and Mann-Whitney U test were used to investigate the association between dual-tracer PET findings, clinical and histopathological data. p-value significance was defined below the 0.05 level. Patients’ mean age was 70 years (range: 49–84) and mean PSA at time of PET/MR scans was 1.88 ng/mL (range: 0.21–14.4). A higher detection rate was observed for 68Ga-PSMA PET/MRI, with more lesions being detected compared to 68Ga-DOTA-RM2 PET/MRI (26/35 patients, 95 lesions vs. 15/31 patients, 41 lesions; p = 0.016 and 0.002). 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI findings were discordant in 11/31 patients; among these, 10 were 68Ga-PSMA positive (9/10 confirmed as true positive and 1/10 as false positive by follow-up examination). Patients with higher levels of PSA and shorter PSA doubling time (DT) presented more lesions on 68Ga-PSMA PET/MRI (p = 0.006 and 0.044), while no association was found between PET findings and Gleason score. 68Ga-PSMA has a higher detection rate than 68Ga-DOTA-RM2 in detecting PCa recurrence. The number of 68Ga-PSMA PET positive lesions is associated with higher levels of PSA and shorter PSA DT, thus representing potential prognostic factors.</description><subject>Antigens</subject><subject>Cancer therapies</subject><subject>Gastrin</subject><subject>Gastrin-releasing peptide</subject><subject>Image processing</subject><subject>Lesions</subject><subject>Localization</subject><subject>Magnetic resonance imaging</subject><subject>Metastasis</subject><subject>Patients</subject><subject>Pelvis</subject><subject>Positron emission tomography</subject><subject>Prostate cancer</subject><subject>Proteins</subject><subject>Tomography</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkV9v2yAUxdG0qq26PvcVaS978QJcG8weJkVJ_0mNGqV5tzDGCZUDGeBN-xj9xrPdatrKC3DOT-dyuQhdUfIVQJKZVk6bEGlOGAHIP6BzRgTLOJf5x3_OZ-gyxmcyLAAquDhFZ1CQAnIpz9ELL29Vtn5azbFyDZ5uy8ftPNusGF5fb2erzT22Dm-M7kMwLuF18DGpZPBiKv8NL63auUGzGq9NaH04jMYUN4_Ra6uS9Q7_smmPF511Vqtucu9sTP6o0t53fjepS5XUJ3TSqi6ay7f9Am1vrreLu-zh8fZ-MX_INLAyZaUiSsmm4A2ntCZUyxKKvDS6rqGgreBlOcimkGDqtm5ySaBtYeBlQ4VhcIG-v8Ye-_pgGj20FlRXHYM9qPC78spW_zvO7qud_1mVQoCQY8CXt4Dgf_QmpupgozZdp5zxfawYZ4yVDAo-oJ_foc--D27obqQoE0LCSM1eKT38cAym_fsYSqpx4NW7gcMfm0mdeg</recordid><startdate>20220111</startdate><enddate>20220111</enddate><creator>Mapelli, Paola</creator><creator>Ghezzo, Samuele</creator><creator>Samanes Gajate, Ana Maria</creator><creator>Preza, Erik</creator><creator>Palmisano, Anna</creator><creator>Cucchiara, Vito</creator><creator>Brembilla, Giorgio</creator><creator>Bezzi, Carolina</creator><creator>Rigamonti, Riccardo</creator><creator>Magnani, Patrizia</creator><creator>Toninelli, Elisa</creator><creator>Bettinardi, Valentino</creator><creator>Suardi, Nazareno</creator><creator>Gianolli, Luigi</creator><creator>Scifo, Paola</creator><creator>Briganti, Alberto</creator><creator>De Cobelli, Francesco</creator><creator>Esposito, Antonio</creator><creator>Picchio, Maria</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7532-6211</orcidid><orcidid>https://orcid.org/0000-0002-7765-6759</orcidid><orcidid>https://orcid.org/0000-0003-3554-4609</orcidid><orcidid>https://orcid.org/0000-0003-4014-3711</orcidid></search><sort><creationdate>20220111</creationdate><title>68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data</title><author>Mapelli, Paola ; Ghezzo, Samuele ; Samanes Gajate, Ana Maria ; Preza, Erik ; Palmisano, Anna ; Cucchiara, Vito ; Brembilla, Giorgio ; Bezzi, Carolina ; Rigamonti, Riccardo ; Magnani, Patrizia ; Toninelli, Elisa ; Bettinardi, Valentino ; Suardi, Nazareno ; Gianolli, Luigi ; Scifo, Paola ; Briganti, Alberto ; De Cobelli, Francesco ; Esposito, Antonio ; Picchio, Maria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c328t-8a0aa9d56d611b01c983548ecbb351f76881b0e593ebfbd4903ff3d569d17e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Cancer therapies</topic><topic>Gastrin</topic><topic>Gastrin-releasing peptide</topic><topic>Image processing</topic><topic>Lesions</topic><topic>Localization</topic><topic>Magnetic resonance imaging</topic><topic>Metastasis</topic><topic>Patients</topic><topic>Pelvis</topic><topic>Positron emission tomography</topic><topic>Prostate cancer</topic><topic>Proteins</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mapelli, Paola</creatorcontrib><creatorcontrib>Ghezzo, Samuele</creatorcontrib><creatorcontrib>Samanes Gajate, Ana Maria</creatorcontrib><creatorcontrib>Preza, Erik</creatorcontrib><creatorcontrib>Palmisano, Anna</creatorcontrib><creatorcontrib>Cucchiara, Vito</creatorcontrib><creatorcontrib>Brembilla, Giorgio</creatorcontrib><creatorcontrib>Bezzi, Carolina</creatorcontrib><creatorcontrib>Rigamonti, Riccardo</creatorcontrib><creatorcontrib>Magnani, Patrizia</creatorcontrib><creatorcontrib>Toninelli, Elisa</creatorcontrib><creatorcontrib>Bettinardi, Valentino</creatorcontrib><creatorcontrib>Suardi, Nazareno</creatorcontrib><creatorcontrib>Gianolli, Luigi</creatorcontrib><creatorcontrib>Scifo, Paola</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><creatorcontrib>De Cobelli, Francesco</creatorcontrib><creatorcontrib>Esposito, Antonio</creatorcontrib><creatorcontrib>Picchio, Maria</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mapelli, Paola</au><au>Ghezzo, Samuele</au><au>Samanes Gajate, Ana Maria</au><au>Preza, Erik</au><au>Palmisano, Anna</au><au>Cucchiara, Vito</au><au>Brembilla, Giorgio</au><au>Bezzi, Carolina</au><au>Rigamonti, Riccardo</au><au>Magnani, Patrizia</au><au>Toninelli, Elisa</au><au>Bettinardi, Valentino</au><au>Suardi, Nazareno</au><au>Gianolli, Luigi</au><au>Scifo, Paola</au><au>Briganti, Alberto</au><au>De Cobelli, Francesco</au><au>Esposito, Antonio</au><au>Picchio, Maria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data</atitle><jtitle>Cancers</jtitle><date>2022-01-11</date><risdate>2022</risdate><volume>14</volume><issue>2</issue><spage>334</spage><pages>334-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The aim of the present study is to investigate and compare the performances of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in identifying recurrent prostate cancer (PCa) after primary treatment and to explore the association of dual-tracer PET findings with clinical and histopathological characteristics. Thirty-five patients with biochemical relapse (BCR) of PCa underwent 68Ga PSMA PET/MRI for restaging purpose, with 31/35 also undergoing 68Ga-DOTA-RM2 PET/MRI scan within 16 days (mean: 3 days, range: 2–16 days). Qualitative and quantitative image analysis has been performed by comparing 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI findings both on a patient and lesion basis. Clinical and instrumental follow-up was used to validate PET findings. Fisher’s exact test and Mann-Whitney U test were used to investigate the association between dual-tracer PET findings, clinical and histopathological data. p-value significance was defined below the 0.05 level. Patients’ mean age was 70 years (range: 49–84) and mean PSA at time of PET/MR scans was 1.88 ng/mL (range: 0.21–14.4). A higher detection rate was observed for 68Ga-PSMA PET/MRI, with more lesions being detected compared to 68Ga-DOTA-RM2 PET/MRI (26/35 patients, 95 lesions vs. 15/31 patients, 41 lesions; p = 0.016 and 0.002). 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI findings were discordant in 11/31 patients; among these, 10 were 68Ga-PSMA positive (9/10 confirmed as true positive and 1/10 as false positive by follow-up examination). Patients with higher levels of PSA and shorter PSA doubling time (DT) presented more lesions on 68Ga-PSMA PET/MRI (p = 0.006 and 0.044), while no association was found between PET findings and Gleason score. 68Ga-PSMA has a higher detection rate than 68Ga-DOTA-RM2 in detecting PCa recurrence. The number of 68Ga-PSMA PET positive lesions is associated with higher levels of PSA and shorter PSA DT, thus representing potential prognostic factors.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>35053499</pmid><doi>10.3390/cancers14020334</doi><orcidid>https://orcid.org/0000-0002-7532-6211</orcidid><orcidid>https://orcid.org/0000-0002-7765-6759</orcidid><orcidid>https://orcid.org/0000-0003-3554-4609</orcidid><orcidid>https://orcid.org/0000-0003-4014-3711</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-01, Vol.14 (2), p.334 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8773792 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antigens Cancer therapies Gastrin Gastrin-releasing peptide Image processing Lesions Localization Magnetic resonance imaging Metastasis Patients Pelvis Positron emission tomography Prostate cancer Proteins Tomography |
| title | 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T17%3A36%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=68Ga-PSMA%20and%2068Ga-DOTA-RM2%20PET/MRI%20in%20Recurrent%20Prostate%20Cancer:%20Diagnostic%20Performance%20and%20Association%20with%20Clinical%20and%20Histopathological%20Data&rft.jtitle=Cancers&rft.au=Mapelli,%20Paola&rft.date=2022-01-11&rft.volume=14&rft.issue=2&rft.spage=334&rft.pages=334-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14020334&rft_dat=%3Cproquest_pubme%3E2622282356%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2621277936&rft_id=info:pmid/35053499&rfr_iscdi=true |